Drug intelligence / Profile preview

Oph1

Development stage: Phase 1
Administration: Ophthalmic

Overview

Oph1 is referenced as an investigational drug that was evaluated in a Phase 0 clinical trial for tolerability compared to Restasis (cyclosporine) in healthy volunteers. The available information does not specify its mechanism of action, molecular target, or therapeutic indication beyond the context of this feasibility study. There is no evidence from the provided sources that it has reached advanced clinical development or approval for any disease[1].

Other names: Oph1Oph-1Oph 1

Beyond the preview

Go deeper on Oph1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oph1.

Explore the full profile